New pill aims to halt liver scarring in hepatitis b and fatty liver patients
NCT ID NCT07364448
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This study tests a drug called hydronidone in 200 adults with liver fibrosis caused by chronic hepatitis B or fatty liver disease. Participants take three capsules three times daily for 28 days. The main goal is to check for side effects, not to measure how well the drug works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Hydronidone capsules
- What this could lead to
- If successful, this could point toward a new treatment option to control liver fibrosis in people with chronic hepatitis B or fatty liver disease.
- What could go wrong
- This is an early Phase 2 trial with only 200 participants and no placebo group, so results may not confirm effectiveness. The 28-day treatment period is short, and long-term safety or benefit is unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B WITH HEPATIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jilin University First Hospital
Jilin City, Changchun, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.